Evidence map›Paper›PMID 39972349›Full record

ArticleCell communication and signaling : CCS2025

Cullin-RING ligase BioE3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous Cereblon ubiquitome.

Laura Merino-Cacho, Orhi Barroso-Gomila, Mónica Pozo-Rodríguez, Veronica Muratore, Claudia Guinea-Pérez, Álvaro Serrano, Coralia Pérez, Sandra Cano-López, Ainhoa Urcullu, Mikel Azkargorta and 7 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Laura Merino-CachoCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Orhi Barroso-GomilaCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Mónica Pozo-RodríguezCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Veronica MuratoreCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Claudia Guinea-PérezCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Álvaro SerranoDepartment of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
Coralia PérezCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Sandra Cano-LópezCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Ainhoa UrculluCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Mikel AzkargortaCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Ibon IloroCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Carles GaldeanoInstitute of Theoretical and Computational Chemistry (IQTC), School of Chemistry and Physics, University of Barcelona, 08028, Barcelona, Spain.
Jordi Juárez-JiménezDepartment of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, School of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
Ugo MayorBiochemistry and Molecular Biology Department, University of the Basque Country, Leioa, Spain.
Felix ElortzaCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain.
Rosa BarrioCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain. rbarrio@cicbiogune.es.
James D SutherlandCenter for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain. jsutherland@cicbiogune.es.

Funding

Computational Biology Drug Design Consolidated Research Group, Generalitat de Catalunya 2021SGR00671Cooperation for Science & Technology COST Action ProteoCure CA20113Diputación Foral de Bizkaia 6/12/TT/2023 /00001HORIZON EUROPE Marie Sklodowska-Curie Actions 765445-EU, UbiCODE ProgramMinisterio de Ciencia e Innovación PRE2018-086230Ministerio de Ciencia e Innovación PRE2021-099359Ministerio de Ciencia e Innovación PRE2022-104553Ministerio de Ciencia e Innovación PREP2023-000294Ministerio de Ciencia, Innovación y Universidades CNS2022-135307Ministerio de Ciencia, Innovación y Universidades PID2020-117333GB-I00Ministerio de Ciencia, Innovación y Universidades PID2023-147399NB-I00, PID2020-114178GB-I00, CEX2021-001136-S, CEX2021-001202-MMinisterio de Universidades FPU20/05282Red Española de Supercomputación BCV-2021-3-0006, BCV-2021-2-0005
6 · The paper itself

Abstract

backgroundThe specificity of the ubiquitination process is mediated by the E3 ligases. Discriminating genuine substrates of E3s from mere interacting proteins is one of the major challenges in the field. We previously developed BioE3, a biotin-based approach that uses BirA-E3 fusions together with ubiquitin fused to a low-affinity AviTag to obtain a site-specific and proximity-dependent biotinylation of the substrates. We proved the suitability of BioE3 to identify targets of RING and HECT-type E3 ligases.

methodsBioE3 experiments were performed in HEK293FT and U2OS stable cell lines expressing TRIPZ-bio

resultsHere we demonstrate that BioE3 is suitable for the multi-protein complex Cullin-RING E3s ligases (CRLs), the most utilized E3-type for targeted protein degradation (TPD) strategies. Using CRBN as proof of concept, one of the substrate receptors of CRL4 E3 ligase, we identified both endogenous substrates and novel neosubstrates upon pomalidomide treatment, including CSDE1 which contains a G-loop motif potentially involved in the binding to CRBN in presence of pomalidomide. Importantly, we observed a major rearrangement of the endogenous ubiquitination landscape upon treatment with this molecular glue.

conclusionsThe ability of BioE3 to detect and compare both substrates and neosubstrates, as well as how substrates change in response to treatments, will facilitate both on-target and off-target identifications and offer a broader characterization and validation of TPD compounds, like molecular glues and PROTACs.

Indexed as

Adaptor Proteins, Signal TransducingUbiquitinationUbiquitin-Protein LigasesHEK293 CellsHumansSubstrate SpecificityThalidomideAdaptor Proteins, Signal TransducingCRBN protein, humanThalidomideUbiquitin-Protein LigasesE3 ligasesImmunomodulatory drugsMolecular GlueTargeted Protein DegradationUbiquitin

Identifiers

PMID39972349
PMCPMC11841277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.